ChroMedX Announces Closing of Private Placement
Toronto, Ontario–(Newsfile Corp. – November 20, 2017) – ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the “Company”) is pleased to announce that it has closed a non-brokered private placement (the “Offering”) of 7,570,500 units (“Units”) at a price of $0.20 per Unit for aggregate gross proceeds of $1,514,100. Each Unit is comprised of one common share of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”). Each Warrant entitles the holder thereof to acquire one Common Share at a price of $0.30 for a period of two years from the closing of the Offering.
Certain eligible persons (the “Finders”) were paid a cash commission equal to 8% of the proceeds raised from subscribers introduced to the Company by such Finder, and also issued broker warrants (the “Broker Warrants”) equal to 8% of the securities purchased by such subscribers. Each Broker Warrant entitles the holder thereof to purchase one Common Share at a price of $0.20 for a period of two years from the closing of the Offering.
All securities issued in connection with the Offering will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation. The proceeds of the Offering will be used for developing prototypes, marketing and general working capital purposes.
The Offering constituted a related party transaction within the meaning of Multilateral Instrument 61-101 (“MI 61-101”) as insiders of the Company subscribed for an aggregate of 300,000 Units. The Company is relying on the exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, as the fair market value of the participation in the Offering by the insiders does not exceed 25% of the market capitalization of the Company, as determined in accordance with MI 61-101. The Company did not file a material change report in respect of the related party transaction at least 21 days before the closing Offering, which the Company deems reasonable in the circumstances in order to avail itself of the proceeds of the private placement and complete the Offering in an expeditious manner.
The Company also announces that it has granted an aggregate of 3,212,000 options to purchase common shares of the Company exercisable at a price of $0.27 per share and expiring on November 20, 2022, to certain directors, officers and consultants of the Company.
About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company’s issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.
Office: 647-872-9982 ext. 2
TF: 1-844-247-6633 ext. 2